Reportstack has announced a new market research publication on Investigation Report on China Quetiapine Market, 2009-2018. Schizophrenia is a common mental disorder. As a chronic disease, schizophrenia can lead to recurrent or persistent symptoms in most patients' whole life. As Chinese economy and society develops, life and work here has become increasingly stressful. As a result, recurrence rate of schizophrenia has also increased. Statistics shows that the number of schizophrene in China has exceeded 10 million by the end of 2013, and it is still rising year after year.
Quetiapine is originally developed by Astra Zeneca and has curative effect on various schizophrenic symptoms. It was firstly approved to the U.K. market in July 1997 and to the U.S. market on September 26, 1997 by FDA with the trade name "Seroquel". Patent of this product expired on March 26, 2012. To prolong its life cycle, long-acting release formulation of quetiapine developed by Astra Zeneca was approved to the U.S. market on May 17, 2007 with the trade name "Seroquel XR", which extends its patent protection to November 28, 2017. After that it has come into markets of several countries sequentially, such as Germany and China.
In 2012, global sales revenue of Seroquel and Seroquel XR was USD 2,803 million, of which the former dropped by 70% to USD 1,294 million while the later increased to USD 1,509 million.
The moment the patent of Seroquel expired, it became target of many generic drug manufacturers.
On March 22, 2012, the U.K. High Court ruled that the patent of Seroquel XR prescription was invalid. However, District Court of New Jersey later ruled that patent of Seroquel XR was valid. Consequently, the production of Seroquel generic drug by Anchen, Osmotica, Torrent and Mylan Pharmaceutical Company has violated the patent of Seroquel XR prescription, which expires in 2017.
On March 27, 2012, Teva Pharmaceutical Industries Limited launched generic drugs of Seroquel and Seroquel XL in the U.K. on the same day, Dr. Reddy's Lab from India launched Seroquel generic drug in the U.S. Astra Zeneca permitted Intelli to sell generic drug of Seroquel XL from November 2016.
Quetiapine produced by Astra Zeneca was approved to China in 2000 with the trade name "Seroquel". In the same year, Hunan Dongting Pharmaceutical Co., Ltd. became the first approved manufacturer to produce quetiapine raw material and troche with the brand name "Qi Wei". In 2003, Suzhou Pharmaceutical Group Co., Ltd. was also approved to produce quetiapine raw material and troche with the brand name "Shu Si". Moreover, Chongqing Fuan Pharmaceutical Co., Ltd. and Zhejiang Supor Pharmaceuticals Co., Ltd. received raw material approvals respectively in 2011 and 2012. Many pharmaceutical manufacturers in China have reported quetiapine tablet production, among which Suzhou Pharmaceutical Group Co., Ltd. reported the production of quetiapine sustained-release tablets in 2012.
According to investigation, Seroquel produced by Astra Zeneca takes up over 70% of quetiapine market in Chinese sample hospitals, followed by Qi Wei produced by Hunan Dongting Pharmaceutical Co., Ltd. and Shu Si produced by Suzhou Pharmaceutical Group Co., Ltd.
The CAGR of sales value of quetiapine surpassed 25% in Chinese sample hospitals from 2005 to 2012. Its growth rate has been declining slightly since 2010, but an annual growth rate of 10% is basically maintained. Quetiapine is now listed in Guidelines of Mental Illness Treatment in China. It is considered as a first-line drug to treat schizophrenia in Chinese market. Estimation indicates that the number of schizophrene in China will continue to rise in the next few years, leaving huge market space to grow for quetiapine.
Through this report, the readers can acquire the following information:
-Incidence of Schizophrenia in China
-Market Share of Major Quetiapine Manufacturers in China Sample Hospitals
-Sales price of Quetiapine in China Hospital Market
-Production Status of Quetiapine Generic Drug in China
-Major Quetiapine Manufacturers in China
-Prospect of China Quetiapine Market
The following enterprises and people are recommended to purchase this report:
-Anti-schizophrenia Medication Manufacturers
-Medical Institutions
Quetiapine is originally developed by Astra Zeneca and has curative effect on various schizophrenic symptoms. It was firstly approved to the U.K. market in July 1997 and to the U.S. market on September 26, 1997 by FDA with the trade name "Seroquel". Patent of this product expired on March 26, 2012. To prolong its life cycle, long-acting release formulation of quetiapine developed by Astra Zeneca was approved to the U.S. market on May 17, 2007 with the trade name "Seroquel XR", which extends its patent protection to November 28, 2017. After that it has come into markets of several countries sequentially, such as Germany and China.
In 2012, global sales revenue of Seroquel and Seroquel XR was USD 2,803 million, of which the former dropped by 70% to USD 1,294 million while the later increased to USD 1,509 million.
The moment the patent of Seroquel expired, it became target of many generic drug manufacturers.
On March 22, 2012, the U.K. High Court ruled that the patent of Seroquel XR prescription was invalid. However, District Court of New Jersey later ruled that patent of Seroquel XR was valid. Consequently, the production of Seroquel generic drug by Anchen, Osmotica, Torrent and Mylan Pharmaceutical Company has violated the patent of Seroquel XR prescription, which expires in 2017.
On March 27, 2012, Teva Pharmaceutical Industries Limited launched generic drugs of Seroquel and Seroquel XL in the U.K. on the same day, Dr. Reddy's Lab from India launched Seroquel generic drug in the U.S. Astra Zeneca permitted Intelli to sell generic drug of Seroquel XL from November 2016.
Quetiapine produced by Astra Zeneca was approved to China in 2000 with the trade name "Seroquel". In the same year, Hunan Dongting Pharmaceutical Co., Ltd. became the first approved manufacturer to produce quetiapine raw material and troche with the brand name "Qi Wei". In 2003, Suzhou Pharmaceutical Group Co., Ltd. was also approved to produce quetiapine raw material and troche with the brand name "Shu Si". Moreover, Chongqing Fuan Pharmaceutical Co., Ltd. and Zhejiang Supor Pharmaceuticals Co., Ltd. received raw material approvals respectively in 2011 and 2012. Many pharmaceutical manufacturers in China have reported quetiapine tablet production, among which Suzhou Pharmaceutical Group Co., Ltd. reported the production of quetiapine sustained-release tablets in 2012.
According to investigation, Seroquel produced by Astra Zeneca takes up over 70% of quetiapine market in Chinese sample hospitals, followed by Qi Wei produced by Hunan Dongting Pharmaceutical Co., Ltd. and Shu Si produced by Suzhou Pharmaceutical Group Co., Ltd.
The CAGR of sales value of quetiapine surpassed 25% in Chinese sample hospitals from 2005 to 2012. Its growth rate has been declining slightly since 2010, but an annual growth rate of 10% is basically maintained. Quetiapine is now listed in Guidelines of Mental Illness Treatment in China. It is considered as a first-line drug to treat schizophrenia in Chinese market. Estimation indicates that the number of schizophrene in China will continue to rise in the next few years, leaving huge market space to grow for quetiapine.
Through this report, the readers can acquire the following information:
-Incidence of Schizophrenia in China
-Market Share of Major Quetiapine Manufacturers in China Sample Hospitals
-Sales price of Quetiapine in China Hospital Market
-Production Status of Quetiapine Generic Drug in China
-Major Quetiapine Manufacturers in China
-Prospect of China Quetiapine Market
The following enterprises and people are recommended to purchase this report:
-Anti-schizophrenia Medication Manufacturers
-Medical Institutions
To view the table of contents and know more details please visit Investigation Report on China Quetiapine Market, 2009-2018.
